Cross Country Healthcare (CCRN) Stock Overview
Provides talent management services for healthcare clients in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CCRN from our risk checks.
CCRN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cross Country Healthcare, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.22 |
| 52 Week High | US$14.99 |
| 52 Week Low | US$7.43 |
| Beta | 0.45 |
| 1 Month Change | 0.99% |
| 3 Month Change | 39.60% |
| 1 Year Change | 3.36% |
| 3 Year Change | -52.92% |
| 5 Year Change | -16.28% |
| Change since IPO | -35.10% |
Recent News & Updates
Narrative Update • Jun 18
CCRN: Buyout Premium And Margin Recovery Expectations Will Anchor Future Share Performance
Analysts have adjusted their price target for Cross Country Healthcare stock slightly higher to about $12.60, citing updated fair value estimates and a modestly higher assumed future P/E multiple, despite a recent downgrade in Street research. What’s in the News for Cross Country Healthcare Knox Lane LP agreed to acquire Cross Country Healthcare in an all cash transaction valued at about $437 million, with stockholders to receive $13.25 per share, pending approvals and closing conditions.Narrative Update • Jun 02
CCRN: Fair Take On Buyout Premium And Margin Recovery Potential
Analysts recently nudged their price target for Cross Country Healthcare higher, with fair value moving from about $11.67 to $12.44. They cited updated assumptions around revenue growth, margins and future P/E that reflect recent upgrades and price target increases alongside a contrasting downgrade.Seeking Alpha • May 08
Cross Country Healthcare: Time To Cash Out After A New Merger
Summary Cross Country Healthcare is being acquired by P/E firm Knox Lane for $13.25 per share in an all-cash transaction. Knox Lane has a healthcare staffing business in its portfolio, but the merger involves much less consolidation in the industry than the Aya merger did. With only a 1% spread in stock price and acquisition price, there isn't much reason to be long CCRN. I am rating CCRN a hold as I expect the deal to go through with the stock price unchanged. Read the full article on Seeking AlphaNarrative Update • May 03
CCRN: Higher Margin Segments And Travel Nurse Demand Will Support Future Margins
The analyst price target on Cross Country Healthcare has shifted modestly higher, with recent research pointing to a range between $10 and $14. Analysts highlight improving travel nurse demand, confidence in a 4% to 5% adjusted EBITDA margin target by the end of 2026, and opportunities in higher margin segments.Recent updates
Narrative Update • Jun 18
CCRN: Buyout Premium And Margin Recovery Expectations Will Anchor Future Share Performance
Analysts have adjusted their price target for Cross Country Healthcare stock slightly higher to about $12.60, citing updated fair value estimates and a modestly higher assumed future P/E multiple, despite a recent downgrade in Street research. What’s in the News for Cross Country Healthcare Knox Lane LP agreed to acquire Cross Country Healthcare in an all cash transaction valued at about $437 million, with stockholders to receive $13.25 per share, pending approvals and closing conditions.Narrative Update • Jun 02
CCRN: Fair Take On Buyout Premium And Margin Recovery Potential
Analysts recently nudged their price target for Cross Country Healthcare higher, with fair value moving from about $11.67 to $12.44. They cited updated assumptions around revenue growth, margins and future P/E that reflect recent upgrades and price target increases alongside a contrasting downgrade.Seeking Alpha • May 08
Cross Country Healthcare: Time To Cash Out After A New Merger
Summary Cross Country Healthcare is being acquired by P/E firm Knox Lane for $13.25 per share in an all-cash transaction. Knox Lane has a healthcare staffing business in its portfolio, but the merger involves much less consolidation in the industry than the Aya merger did. With only a 1% spread in stock price and acquisition price, there isn't much reason to be long CCRN. I am rating CCRN a hold as I expect the deal to go through with the stock price unchanged. Read the full article on Seeking AlphaNarrative Update • May 03
CCRN: Higher Margin Segments And Travel Nurse Demand Will Support Future Margins
The analyst price target on Cross Country Healthcare has shifted modestly higher, with recent research pointing to a range between $10 and $14. Analysts highlight improving travel nurse demand, confidence in a 4% to 5% adjusted EBITDA margin target by the end of 2026, and opportunities in higher margin segments.Narrative Update • Apr 17
CCRN: Higher Margin Segments Will Drive Future EBITDA Margin Upside
Narrative Update on Cross Country Healthcare The analyst price target for Cross Country Healthcare now sits at $11.67, reflecting incremental optimism from analysts who point to improving travel nurse demand, a clearer path toward a 4% to 5% adjusted EBITDA margin by the end of 2026, and opportunities across higher margin segments. Analyst Commentary Recent research highlights a more constructive tone around Cross Country Healthcare, with analysts focusing on the company’s margin ambitions, end market demand, and the mix of higher margin segments when thinking about valuation and execution risk.Narrative Update • Apr 03
CCRN: Margin Execution And Travel Nurse Demand Will Drive Bullish Thesis
Analysts have nudged their price targets for Cross Country Healthcare higher, with moves such as UBS lifting its target to $10 from $9 and Benchmark setting a $14 target. They cited improving travel nurse demand, confidence in a 4% to 5% adjusted EBITDA margin target by the end of 2026, and a clearer path toward higher margin segments and operating leverage.
New Narrative • Mar 20
Flexible Labor And Tech-Enabled Staffing Will Reshape Earnings Power Over The Next Decade
Catalysts About Cross Country Healthcare Cross Country Healthcare provides health care workforce solutions and staffing services across hospitals, home-based care, education and physician staffing. What are the underlying business or industry changes driving this perspective?Narrative Update • Mar 20
CCRN: Margin Execution And Share Repurchases Will Shape Bullish Outlook
The analyst price target for Cross Country Healthcare has increased to $11.67 from $9.93, with analysts citing improved revenue growth assumptions, a revised profit margin outlook, and a higher assumed future P/E multiple that is supported by recent upgrades and confidence in margin goals and segment opportunities. Analyst Commentary Recent research updates highlight a mix of optimism and caution around Cross Country Healthcare, with price target adjustments clustered in a relatively narrow range and a focus on execution in higher margin areas of the business.
New Narrative • Mar 06
Technology And Mix Shift Will Likely Constrain Margins And Limit Long-Term Upside
Catalysts About Cross Country Healthcare Cross Country Healthcare provides health care staffing and workforce solutions, including travel nursing, allied health, physician staffing and home based and education staffing services. What are the underlying business or industry changes driving this perspective?Narrative Update • Mar 05
CCRN: Neutral Outlook Will Rely On Execution Under Returning Leadership
Analysts have nudged their price target on Cross Country Healthcare slightly higher, citing updated assumptions for revenue trends, modestly lower profit margins, and a slightly richer forward P/E multiple that together still anchor around an estimated fair value of $9.93 per share. Analyst Commentary Recent commentary around Cross Country Healthcare clusters around a neutral stance, with analysts seeing a balance between potential execution upside and practical constraints on growth and profitability at the current valuation near US$9.93 per share.Narrative Update • Feb 19
CCRN: Neutral Coverage And Leadership Change Will Support Future Upside Potential
Analysts have modestly adjusted their price target on Cross Country Healthcare, keeping fair value around $9.93 while fine tuning assumptions on the discount rate, profit margin and future P/E following recent neutral research coverage. Analyst Commentary Bullish Takeaways Bullish analysts view the neutral initiation as consistent with the current fair value estimate around US$9.93, suggesting the stock is reasonably aligned with their refined P/E and discount rate assumptions.Narrative Update • Feb 04
CCRN: Neutral Coverage And Leadership Change Will Shape Balanced Risk Reward Profile
Analysts have nudged their price target for Cross Country Healthcare higher from US$9.66 to about US$9.93, citing updated assumptions around fair value, discount rate, growth, margins, and forward P/E following recent neutral research coverage. Analyst Commentary Bullish Takeaways Bullish analysts see the higher fair value assumptions as consistent with the updated discount rate and P/E inputs, which they view as better aligned with current market expectations for the stock.Narrative Update • Jan 21
CCRN: Leadership Shift And Cancelled Deal Will Shape Balanced Future Outlook
Analysts have adjusted their price target on Cross Country Healthcare to US$9.66. The change reflects slightly updated assumptions around discount rate, revenue growth, profit margin and future P/E, which together point to a modest recalibration of expected risk and earnings power.Narrative Update • Jan 05
CCRN: Leadership Change And Cancelled Deal Will Set Up Future Upside
Analysts have trimmed their price target on Cross Country Healthcare to US$9.66, reflecting updated assumptions around discount rate, profit margin and future P/E. Their fair value view remains broadly unchanged.Narrative Update • Dec 17
CCRN: Improved Margins And Deal Reset Will Drive Future Upside
Analysts have reduced their price target on Cross Country Healthcare from approximately $16.50 to about $9.66 per share, citing slightly weaker revenue growth expectations, a significantly improved profit margin outlook, and a more conservative future price-to-earnings multiple. What's in the News Aya Healthcare cancelled its previously announced all cash acquisition of Cross Country Healthcare, which had valued the company at approximately $615 million, on December 3, 2025 (company filing) The cancelled deal would have taken Cross Country private at $18.61 per share, a roughly 67 percent premium to the pre deal closing price, highlighting a significant reset in market expectations after termination (company filing) As part of the original merger agreement, both Cross Country and Aya were subject to reciprocal $20 million termination fees, underscoring the financial stakes tied to the failed transaction (merger agreement summary) Following the termination, Cross Country remains listed on the NASDAQ, keeping its strategic options and public market funding access intact (company announcement) Leadership stability may come into focus for investors, as the original transaction structure had anticipated continuity of then President and CEO John A.Narrative Update • Dec 03
CCRN: Improved Margins And Lower Expectations Will Drive Future Upside
Analysts have lowered their price target on Cross Country Healthcare from 18.61 dollars to 16.50 dollars, citing slightly higher discount rates, more subdued revenue growth expectations, and a reduced future earnings multiple that is only partially offset by an improved profit margin outlook. Valuation Changes The fair value estimate has fallen moderately, from 18.61 dollars to approximately 16.50 dollars per share.Seeking Alpha • Oct 15
Cross Country Healthcare: The Strong Balance Sheet Provides A Sufficient Margin Of Safety
Summary Healthcare staffing companies saw a massive increase in revenues and profits following the Covid-19 pandemic. In the past year, that trend has reversed as hospitals shore up their staffing needs. CCRN stock is down almost 50% in 2024 as a result. CCRN has a strong balance sheet and a market cap so low that it trades below book value. I lay out my case for why travel nursing is here to stay, and why healthcare staffing companies like CCRN are undervalued at current prices. Read the full article on Seeking Alpha
New Narrative • Sep 24
Travel Nursing And Technology Investments Set To Fuel Remarkable Revenue And Margin Growth
Expansion in the travel nursing segment and strategic Managed Service Provider wins indicate potential for significant revenue and market share growth.Analysis Article • Jul 31
Cross Country Healthcare, Inc.'s (NASDAQ:CCRN) Shares Bounce 30% But Its Business Still Trails The Market
Cross Country Healthcare, Inc. ( NASDAQ:CCRN ) shareholders would be excited to see that the share price has had a...Analysis Article • Feb 22
Benign Growth For Cross Country Healthcare, Inc. (NASDAQ:CCRN) Underpins Stock's 25% Plummet
Cross Country Healthcare, Inc. ( NASDAQ:CCRN ) shares have had a horrible month, losing 25% after a relatively good...Analysis Article • Feb 09
Calculating The Intrinsic Value Of Cross Country Healthcare, Inc. (NASDAQ:CCRN)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Cross Country Healthcare fair value estimate is US$21.93 With...Analysis Article • Oct 09
Cross Country Healthcare (NASDAQ:CCRN) Is Achieving High Returns On Its Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analysis Article • Sep 13
Should You Investigate Cross Country Healthcare, Inc. (NASDAQ:CCRN) At US$23.23?
While Cross Country Healthcare, Inc. ( NASDAQ:CCRN ) might not be the most widely known stock at the moment, it...Analysis Article • Aug 19
These 4 Measures Indicate That Cross Country Healthcare (NASDAQ:CCRN) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • Jun 26
Returns on Capital Paint A Bright Future For Cross Country Healthcare (NASDAQ:CCRN)
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analysis Article • Jun 08
At US$27.39, Is It Time To Put Cross Country Healthcare, Inc. (NASDAQ:CCRN) On Your Watch List?
Cross Country Healthcare, Inc. ( NASDAQ:CCRN ), is not the largest company out there, but it led the NASDAQGS gainers...Shareholder Returns
| CCRN | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0.4% | 5.9% | -2.5% |
| 1Y | 3.4% | 22.1% | 19.0% |
Return vs Industry: CCRN underperformed the US Healthcare industry which returned 22.1% over the past year.
Return vs Market: CCRN underperformed the US Market which returned 19% over the past year.
Price Volatility
| CCRN volatility | |
|---|---|
| CCRN Average Weekly Movement | 8.9% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CCRN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CCRN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 7,890 | Kevin Clark | www.crosscountry.com |
Cross Country Healthcare, Inc. provides talent management services for healthcare clients in the United States. The company operates in two segments: Nurse and Allied Staffing, and Physician Staffing. The Nurse and Allied Staffing segment provides traditional staffing, recruiting, and value-added total talent solutions, including temporary and permanent placement of travel nurse and allied professionals, per diem, and healthcare leaders within nursing, allied, human resources, and finance; vendor neutral and managed services programs; and education healthcare, caregiver services, and outsourcing services.
Cross Country Healthcare, Inc. Fundamentals Summary
| CCRN fundamental statistics | |
|---|---|
| Market cap | US$409.93m |
| Earnings (TTM) | -US$98.63m |
| Revenue (TTM) | US$1.00b |
0.4x
P/S Ratio-4.2x
P/E RatioIs CCRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CCRN income statement (TTM) | |
|---|---|
| Revenue | US$1.00b |
| Cost of Revenue | US$799.44m |
| Gross Profit | US$202.50m |
| Other Expenses | US$301.13m |
| Earnings | -US$98.63m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.18 |
| Gross Margin | 20.21% |
| Net Profit Margin | -9.84% |
| Debt/Equity Ratio | 0% |
How did CCRN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/28 04:18 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cross Country Healthcare, Inc. is covered by 21 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin Steinke | Barrington Research Associates, Inc. |
| William Sutherland | Benchmark Company |
| Jeffrey Silber | BMO Capital Markets Equity Research |